satraplatin
Selected indexed studies
- Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies. (Anticancer Res, 2022) [PMID:35347000]
- Satraplatin for the therapy of castration-resistant prostate cancer. (Future Oncol, 2009) [PMID:19792961]
- The resurgence of platinum-based cancer chemotherapy. (Nat Rev Cancer, 2007) [PMID:17625587]
_Worker-drafted node — pending editorial review._
Connections
satraplatin is a side effect of
Sources
- Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies. (2022) pubmed
- Satraplatin for the therapy of castration-resistant prostate cancer. (2009) pubmed
- The resurgence of platinum-based cancer chemotherapy. (2007) pubmed
- Satraplatin: leading the new generation of oral platinum agents. (2009) pubmed
- Clinical and pharmacokinetic evaluation of satraplatin. (2012) pubmed
- Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. (2007) pubmed
- Satraplatin: an orally available platinum analog for the treatment of cancer. (2006) pubmed
- Nanoparticle-Mediated Delivery of Satraplatin to Overcome Cisplatin Drug Resistance. (2023) pubmed
- Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. (2023) pubmed
- Current status and future prospects for satraplatin, an oral platinum analogue. (2008) pubmed